International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
Международные клинические руководства по лечению острого неосложнённого цистита и пиелонефрита у женщин: обновление 2010 г. от Общества инфекционных заболеваний США и Европейского общества по микробиологии и инфекционным болезням
2011-02-03
SCID: 54.1/ev5gtd8b
Discuss with AI
IDSA-ESCMID guidelinesacute uncomplicated cystitisantimicrobial resistance prevalenceecological adverse effects (collateral damage)pyelonephritis in women
Figures from the paper
Abstract (AI)
A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.
Key Findings
1
An international expert panel (IDSA and ESCMID) updated 1999 guidelines for treating acute uncomplicated cystitis and pyelonephritis in women (2010).
2
Ecological adverse effects of antimicrobial therapy (collateral damage) were incorporated into recommendation rankings.
3
Guidelines focus specifically on premenopausal, non-pregnant women without urological abnormalities or co-morbidities.
4
In vitro antimicrobial resistance prevalence was explicitly considered when formulating treatment recommendations.
5
Multiple professional societies co-sponsored the update, including ACOG, AUA, AMMI-Canada, and SAEM, indicating broad clinical endorsement.
Research Object
Premenopausal, non-pregnant women with acute uncomplicated cystitis and pyelonephritis (no known urological abnormalities or co-morbidities)
Research Subject
Clinical treatment recommendations for acute uncomplicated cystitis and pyelonephritis in this population, considering antimicrobial choice, in vitro resistance prevalence, and ecological adverse effects (collateral damage)
Publication Details
Publication Date
2011-02-03
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by2
Impact of a smartphone app on prescriber adherence to antibiotic guidelines in adult patients with community acquired pneumonia or urinary tract infections2019
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya2018